Skip to content
drillr.ai
Sign up

00013.HK

HUTCHMED (China) Limited

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK

HKD 20.78
−1.80%
Ask drillr

  • Oct 27, 2026, 04:14 UTC

    Duality Biotherapeutics, Inc. reported positive phase III SAFFRON results for osimertinib plus savolitinib in 338 patients with EGFR-mutated, MET-overexpressing or amplified non-small cell lung cancer, including median progression-free survival of 7.6 months versus 5.4 months with chemotherapy and median overall survival of 17.8 months versus 12.9 months.

    Source:

  • Oct 27, 2026, 00:11 UTC

    HUTCHMED (China) Ltd. announced that it will hold an online expert discussion with CITIGROUP INC on savolitinib data and treatment strategies for MET-driven non-small cell lung cancer.

    Source:

  • Oct 26, 2026, 08:49 UTC

    HUTCHMED (China) Ltd. announced positive Phase III SANOVO results showing that savolitinib plus osimertinib reduced the risk of disease progression or death by 44% overall and 55% among patients with high MET overexpression, compared with osimertinib alone.

    Source:

  • Oct 21, 2026, 00:58 UTC

    Hutchison MediPharma (Shanghai) expects to receive a $110 million upfront payment from a GSK plc subsidiary in the near term under the completed HMPL-A830 licensing agreement.

    Source:

  • Oct 21, 2026, 00:05 UTC

    HUTCHMED (China) Ltd. announced that its subsidiary HUTCHMED (China) Ltd. and a GSK plc subsidiary completed an exclusive development and licensing agreement for HMPL-A830 outside mainland China, Hong Kong, Macau and Taiwan.

    Source:

  • Sep 28, 2026, 00:02 UTC

    HUTCHMED announced the start of the Phase Ia portion of a global clinical trial of HMPL-A830 for unresectable advanced or metastatic solid tumors, with the first patient dosed in China on September 24, 2026.

    Source:

  • Sep 24, 2026, 00:01 UTC

    HUTCHMED announced that new and updated clinical data from several studies of its discovered compounds, including two positive Phase III studies of the savolitinib and osimertinib combination, will be presented at the ESMO Congress 2026 in Madrid on October 23-27, 2026.

    Source:

  • Sep 3, 2026, 04:12 UTC

    Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.

    Source:

  • Aug 28, 2026, 00:00 UTC

    China's National Medical Products Administration approved HUTCHMED's ATLED (fanregratinib) for the treatment of patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.

    Source:

  • Jun 25, 2026, 05:56 UTC

    HUTCHMED announced that its registrational Phase 2 trial of Fanregratinib met the primary endpoint in bile duct cancer, and its New Drug Application for the drug was accepted for review and granted priority.

    Source: